Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UBS0
UPID:
KS6B2_HUMAN
Alternative names:
70 kDa ribosomal protein S6 kinase 2; S6 kinase-related kinase; Serine/threonine-protein kinase 14B; p70 ribosomal S6 kinase beta
Alternative UPACC:
Q9UBS0; B2RMZ9; B4DML8; O94809; Q9UEC1
Background:
Ribosomal protein S6 kinase beta-2, also known as 70 kDa ribosomal protein S6 kinase 2, plays a pivotal role in cell proliferation, growth, and cycle progression. It specifically phosphorylates ribosomal protein S6, acting downstream of mTOR signaling in response to growth factors and nutrients. This action is regulated by an alternative pathway involving MEAK7, highlighting its critical function in cellular signaling pathways.
Therapeutic significance:
Understanding the role of Ribosomal protein S6 kinase beta-2 could open doors to potential therapeutic strategies.